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Abstract: Alzheimer’s disease (AD) is becoming one of the most disturbing health and socioeconomic
problems nowadays, as it is a neurodegenerative pathology with no treatment, which is expected to
grow further due to population ageing. Actual treatments for AD produce only a modest amelioration
of symptoms, although there is a constant ongoing research of new therapeutic strategies oriented
to improve the amelioration of the symptoms, and even to completely cure the disease. A principal
feature of AD is the presence of neurofibrillary tangles (NFT) induced by the aberrant phosphorylation
of the microtubule-associated protein tau in the brains of affected individuals. Glycogen synthetase
kinase-3 beta (GSK3β), casein kinase 1 delta (CK1δ), dual-specificity tyrosine phosphorylation
regulated kinase 1A (DYRK1A) and dual-specificity kinase cdc2-like kinase 1 (CLK1) have been
identified as the principal proteins involved in this process. Due to this, the inhibition of these kinases
has been proposed as a plausible therapeutic strategy to fight AD. In this study, we tested in silico
the inhibitory activity of different marine natural compounds, as well as newly-designed molecules
from some of them, over the mentioned protein kinases, finding some new possible inhibitors with
potential therapeutic application.
Keywords: meridianins; kororamide A–B; convolutamine I–J; indole scaffold; computer-aided drug
design; Alzheimer’s disease; GSK3β; CK1δ; DYRK1A; CLK1
1. Introduction
Constituting about 2% of all human genes, protein kinases are an important family of enzymes
with a critical role in signal transduction pathway by modification of substrate activity. They are also
responsible to control different aspects of cell functions by its phosphorylation activity, which plays a
critical role in intracellular communication during development, and in the function of the nervous
and immune systems [1]. Due to that, kinases are related with many diseases, such as Alzheimer’s
Disease (AD) or Amyotrophic Lateral Sclerosis (ALS), among others. AD, the neurodegenerative
pathology that is considered to represent the most common type of dementia (60–80% of the total
cases), is characterized by memory deterioration and modification of cognitive abilities. Alzheimer’s
pathologies are associated with the presence of senile plaques (SP), mainly composed by beta-amyloid
(Aβ) peptides, and neurofibrillary tangles (NFT), that are intraneuronal aggregations principally
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composed of abnormal phosphorylated tau protein. Tau is a soluble microtubule-binding protein and
is hyperphosphorylated in AD. Tau phosphorylation is regulated by a balance between tau kinase
and phosphatase activities. Anti-phosphorylation strategies (kinase inhibitors) aim to inhibit these
processes of aggregation and the formation of NFT [2–4]. The abovementioned evidence may suggest
that one of the key strategies is to prevent tau phosphorylation and, thus, combat AD, could be the
inhibition of the protein kinases involved in the tau phosphorylation pathway [4].
Despite the catalytic subunits of many protein kinases are highly conserved, there are several
differences between them that allow to classify protein kinases into subfamilies: (1) Protein kinases
(EC 2.7.10); (2) serine-threonine protein kinases (EC 2.7.11); (3) dual-specificity kinases (those acting on
Ser/Thr and Tyr residues) (EC 2.7.12); (4) protein-histidine kinases (EC 2.7.13); (5) protein-arginine
kinases (EC 2.7.11.14); and (6) other protein kinases (EC 2.7.99), that can be also divided into
sub-subfamilies, such as tau protein kinase (EC 2.7.11.26) and dual-specificity kinase (EC 2.7.12.1).
The main relevant protein kinases involved in tau phosphorylation belong to the sub-subfamilies
tau protein kinase and dual-specificity kinases. As tau protein kinases we find glycogen synthetase
kinase-3 beta (GSK3β) and casein kinase 1 delta (CK1δ), while within dual-specificity kinases, we find
dual-specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) and cdc2-like kinase 1 (CLK1).
Each of them has different roles regarding AD pathology. For GSK3β several authors suggest its link
between Aβ and tau pathology, and in AD patients it has been co-localized with NFT. GSK3β is
suggested to phosphorylate and hipper-phosphorylate tau, while increasing the production of Aβ
and mediating neuronal death. Phosphorylation of tau by GSK3β occurs at 42 sites, where 29 of
them are phosphorylated in AD brains. CK1δ is part of the non-proline-directed protein kinase
(non-PDPK) group inside the tau kinases and its levels are increased while is co-localized with NFT.
CK1δ has an important role on protein aggregation and regulates the microtubule dynamics through
tau phosphorylation at 46 sites, 25 of them phosphorylated in AD brains. DYRK1A phosphorylates the
amyloid precursor protein (APP) and tau proteins, thus increasing neuronal death and the formation
of aggregates. DYRK1A induces tau phosphorylation at serine 202, threonine 212, and serine 404,
sites that were found phosphorylated in AD brains. Finally, cdc2-like kinase 1 (CLK1), one of the four
isoforms conforming an evolutionary conserved group of dual-specificity kinases, is related with AD
by phosphorylating the serine residues in arginine-rich (SR) proteins [2,3,5–15].
The natural-product-inspired design plays an important role in chemical science, as historically
natural products (NP) from diverse sources, such as plants or microbes, have been a rich source of
compounds [16–18]. NP are optimized biologically active metabolites which can be used as a template
to design drug-like compounds [16–18]. Evaluation of Food and Drug Administration (FDA) approved
new molecular entities (NMEs) reveals that NP and their derived compounds represent over one-third
of all NMEs [19], a percentage that is even higher regarding the active compounds in the central
nervous system (CNS) domain [20]. AD is not an exception, and several drug candidates have been
developed from natural sources against the different therapeutic targets identified to date [21–23].
In fact, few reasonable selective and potent GSK3β, CK1δ, DYRK1A, and CLK1 inhibitors have been
described so far, most of them being marine natural products or derived molecules from them [5,24–36].
Recently, it has been shown that meridianins, indole alkaloids from the marine tunicate Aplidium
from the Southern Ocean, could act as inhibitors of these four kinases, with possible inhibitors being
derived from them [24,29,34,37]. In addition to that, kororamide A–B, two brominated alkaloids
from the bryozoan Amathia tortuosa from Australia, showed a phenotypic signature on Parkinson's
disease [38]. Their structure resembles that of meridianins and because of that we decided to study
whether these compounds could also act as inhibitors of the four mentioned kinases, although, as far
as we know, this relation has never been established before. Following with this, and having into
account that marine indole alkaloid conform a large group of compounds with diverse biological
activities that make them attractive starting points for pharmaceutical development [39–41], we have
designed in this work several compounds starting from this well-known scaffold as a core element.
Further, we modified the structural features observed in meridianins and kororamides, as well as with
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the presence of halogen substituents (present also in both chemical species), which has been revealed
as key player to increase activity over these four kinases [24,37,42,43].
To strengthen our initial assumption, we tested the indole scaffold and halogen substituents’ effect
on the inhibition of GSK3β, CK1δ, DYRK1A, and CLK1. To determine the importance of the indole
scaffold for the inhibition of the four studied kinases we also screened the MarinLit database [44] to find
other possible marine compounds that were similar to meridianin F and kororamide A (which were
the best theoretical inhibitors of the four kinases), or at least incorporate the indole scaffold. Thereafter,
we analysed their binding behaviour against them. Moreover, and because of the importance of the
halogen substituents, we decided to investigate whether the halogen substituents are important with
respect to the indole scaffold. To do that, we evaluated the inhibitory behaviour of convolutamine I–J,
two halogenated heterocyclic compounds (that do not present an indole scaffold) extracted from the
bryozoan Amathia tortuosa, and which are structurally and functionally related to kororamide A–B [38].
To sum up, with the general objective to help in the discovery of anti-AD drugs (protein inhibitor/s
to reduce or alleviate AD symptoms), the concrete aim of this study is three-fold: (1) to validate if
kororamide A–B and convolutamine I–J could act as novel inhibitors of the four studied kinases;
(2) to test the indole scaffold importance on the kinases inhibition; and (3) to design new possible
inhibitors of the four kinases starting from meridianin and kororamide indole scaffolds. To do so,
a computational study targeting the adenosine triphosphate (ATP)-binding site of the aforementioned
kinases has been carried out. Computer-aided drug design (CADD) techniques are widely used in
(marine natural product) drug discovery, as they constitute an appropriate tool to rational design
and developing new drug candidates, reducing the time and costs derived from their identification,
characterization, and structure-optimization [45].
2. Results and Discussion
2.1. New Possible GSK3β, CK1δ, DYRK1A, and CLK1 ATP-Competitive Inhibitors
It is generally accepted that the ATP binding site of protein kinases, despite the fact that their
catalytic domains are highly conserved, still remain the most used cavity in (rational) drug design
over this family of proteins [46]. Protein kinases have two different lobes, the N-lobe that is mainly
formed by β-sheets and the C-lobe formed by a helical structure. Between both lobes can be found the
catalytic ATP cavity, which can be divided into five regions: glycine-rich region (GRR), hydrophobic
pocket (HP), adenine region (AR), sugar pocket (SP), and the phosphate binding pocket (PBP) [46–48].
GRR and HP are located at the N-terminal lobe, while SP and PBP are placed at the C-terminal lobe.
AR is in the middle of these regions, providing a link between them (see Figure 1).
All five regions are quite evolutionarily conserved between the kinases, but they are not
identical [37]. GRG is a highly conserved region with a GxGxFG motif (Table 1). The same occurs with
the HP, as all the four kinases have a VAIK motif, except DYRK1A with a Valine (V) residue instead of
an Isoleucine (I). On the contrary, the AR does not seem to have any conserved motif, while SP can be
identified by the PxNxL pattern. For the PBP, only the last aspartate residue (D) seems to be conserved
along the four kinases.
As explained previously, the kinase ATP binding site is the most exploited cavity as far as inhibition
is concerned. Several inhibitors have been reported in the past, some of them being marine natural
products, such as meridianins [28,49]. Most of them can bind to all of these regions, with a different
binding strength depending on their chemical structure. Interestingly, a common feature seems to be
shared between the majority of them: the presence of an indole scaffold [5,25,26,30,31,33–35].
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Figure 1. Structure of the tau protein kinase GSK3β (Protein Data Bank ID (PDB) 3PUP). In the first, 
largest, image the two lobes can be seen in cartoon representation, and in sticks the residues that form 
the ATP cavity. In the top and bottom zoom images all the amino acid residues involved on the ATP 
binding site are shown. Residues in red represent the glycine-rich region (GRR), in blue the 
hydrophobic pocket (HP), in yellow the adenine region (AR), in lilac the sugar pocket (SP), and finally, 
in orange the phosphate binding pocket (PBP). Letters and numbers correspond to their position in 
the amino acid sequence and the PDB file numbering. 
Table 1. Summary of the ATP binding site regions of GSK3β, CK1δ, DYRK1A, and CLK1. Five regions 
are found inside the ATP cavity and their respective residues are shown in a single letter code, as well 
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Figure 1. Structure of the tau protein kinase GSK3β (Protein Data Bank ID (PDB) 3PUP). In the first,
largest, i age the t o lobes can be seen in cartoon representation, and in sticks the residues that
form the ATP cavity. In the top and botto zoom images all the amino acid residues involved on
the ATP binding site are shown. Residues in red represent the glycine-rich region (GRR), in blue the
hydrophobic pocket (HP), in yellow the adenine region (AR), in lilac the sugar pocket (SP), and finally,
in orange the phosphate binding pocket (PB ). Letters and umbers correspond to their positi n in the
amino acid sequence a d the PDB file numbering.
Table 1. Summary of the ATP binding site regions of GSK3β, CK1δ, DYRK1A, and CLK1. Five regions
are found inside the ATP cavity and their respective residues are shown in a single letter code, as well
as their sequence position that corresponds to each PDB file numbering.





































2.2. Kororamide A–B and Convolutamine I–J as Possible Kinase Inhibitors
Ind le alkaloids are ma ine natural products that show specific biol gical activiti s, such as
a ti-inflammatory and serotonin antagonism [41]. Moreover, the therapeutic importance of this
kind of indole scaffolds is well k own, as demonstrated by clinical a d preclinical studies showing
phar acologic l activi ies over neur degenerative diseases, such s AD [41,50]. Within the group of
compounds containing the indole moiety are meridianins, for instance. These molecules constitute
a group of indole alkaloids consisting of an indole framework linked to an aminopyrimidine ring
with a reported inhibitory activity over GSK3β, CK1δ, DYRK1A, and CLK1 [30,34,37]. Within the
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list of indole-containing compounds, structurally similar to meridianins, different molecules can be
found, among which are kororamides. Kororamide A and B are two tribrominated indole alkaloid
compounds from the Southern Ocean bryozoan Amanthia tortuosa. These two marine molecules
share a common halogenated indole scaffold with meridianins and, based on their chemical structural
similarity, one could assume that kororamides could have an inhibitory activity similar to meridianins.
In the same study where kororamide B was identified, three other compounds were also isolated,
kororamide A and convolutamine I and J. The last two compounds do not present an indole scaffold,
but they are halogenated heterocyclic compounds as other known kinase inhibitors [51–53] (Figure 2).
To test this hypothesis, docking calculations and Molecular Dynamics (MD) simulations were carried
out to evaluate if kororamide A–B and convolutamine I–J could behave as meridianins regarding
GSK3β, CK1δ, DYRK1A, and CLK1 binding, thus indicating that they could be potential anti-AD
therapeutic agents.
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Figure 2. Chemical structures of convolutamine I, convolutamine J, kororamide A, kororamide B,
and meridianin F.
In previous studies the presence of halogen atoms was considered important to achieve a good
inhibitory activity over the four studied kinases [24,37]. In order to test whether the presence of a
halogenated indole scaffold, or just the presence of aromatic cycle substituted with halogen atoms,
enhances a high r binding affinity against GSK3β, CK1δ, DYRK1A, and CLK1, w analyse it by means
of docking and MD simulations. Thereafter, we compared the obtained results (Table 2) with the valu s
from kororamide A–B and convolutamine I–J with meridianin F, the most promising compound of the
chemical family (meridianin A-F) [37].
Our results indicate that all the analysed compounds could bind to the ATP binding pocket
of each of the mentioned kinases, thus theoretically acting as ATP competitive inhibitors (Figure 3).
Binding energies obtained after docking and MD simulations (Table 2) show that convolutamine
J and kororamide A tend to have higher energies than convolutamine I and kororamide B. To be
more precise, kororamide A shows better energies when bound against GSK3β, DYRK1A, and CLK1,
while convolutamine J shows better energies over CK1δ. Comparing the energies obtained between the
four tribrominated metabolites found on the bryozoa Amanthia tortuosa and meridianin F, we observe
that the last one has slightly better energies in all cases after MD. These energies do not allow us to
discard any of the compounds as an ATP competitive inhibitor, and we can prioritize kororamide A and
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convolutamine J over kororamide B, and especially over convolutamine I. Additionally, these results do
not allow us to discriminate between which structural features influence most of the binding strength
against the four studied kinases: the indole scaffold, the presence of halogen atoms, or the combination
of both features.
Table 2. Summary of classical rigid docking and molecular mechanics/generalized born surface area
(MM/GBSA) calculations of the two best models selected per meridianin F (F), convolutamine I (I) and
J (J), and kororamide A (A) and B (B). To avoid false positives, each docking calculation was performed
twice (R0/R1). All energies values are kcal/mol. For each target the first (left) column refers to the
results of docking calculations while the second (right) column indicate the binding energy results
obtained after MD calculations.
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With the aim of performing a deeper analysis of the inhibitory behaviour of these compounds,
an interaction and binding mode analysis, of the best and prioritized compounds per target,
was performed. On the ATP catalytic cavity of GSK3β it is observed that key binders I62, F67,
and V70, conforming to the GRR or placed nearby, and Y138 and L188 placed at the C-terminal lobe
placed near the AR and inside SP, respectively, are involved on the kororamide stabilization. For CK1δ
it is observed that convolutamine J is stabilized by interacting with several key binders, like I23,
which is placed near the GGR and A36, M82, and I148 placed at HP, AR, and PBP, respectively. Looking
at DYRK1A ATP cavity, it is observed that kororamide A, at the N-terminal region, is interacting
with I165 and V173, as other known inhibitors like meridianin F or the co-crystal 3RA, both placed
near the GRR. In the same way, kororamide A is also stabilized by A185, which is found at the HP.
At the C-terminal zone it is also interacting with E291 and the L294 conforming PENIL motif and V306
present at the PBP. Finally, kororamide A is also stabilized by L241 and D244, placed near the AR.
Looking at the ATP cavity of CLK1, it can be seen that on the N-terminal domain, L167, F172, and V175
at the GRR, and K191 at the HP, that some of them are known key binders, and are interacting with
kororamide A. Moreover, on the C-lobe, kroramide A is interacting with F241 coming from the FELL
adenin motif, E292, and L295 (a known key binder), placed at the SP, and V324 found at the PBP.
The binding mode of the best compounds, as well as of the four brominated compounds studied,
per target pointed out that they are performing key interactions, most of them previously described
in other well-known inhibitors. This fact together with the obtained binding energies, reinforce their
capacity to behave as inhibitors for the four analyzed kinases, in a similar way to meridianin F.
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Our results indicate that all the analysed compounds could bind to the ATP binding pocket of 
each of the mentioned kinases, thus theoretically acting as ATP competitive inhibitors (Figure 3). 
Binding energies obtained after docking and MD simulations (Table 2) show that convolutamine J 
and kororamide A tend to have higher energies than convolutamine I and kororamide B. To be more 
precise, kororamide A shows better energies when bound against GSK3β, DYRK1A, and CLK1, while 
convolutamine J shows better energies over CK1δ. Comparing the energies obtained between the 
four tribrominated metabolites found on the bryozoa Amanthia tortuosa and meridianin F, we observe 
that the last one has slightly better energies in all cases after MD. These energies do not allow us to 
discard any of the compounds as an ATP competitive inhibitor, and we can prioritize kororamide A 
and convolutamine J over kororamide B, and especially over convolutamine I. Additionally, these 
results do not allow us to discriminate between which structural features influence most of the 
binding strength against the four studied kinases: the indole scaffold, the presence of halogen atoms, 
or the combination of both features. 
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ID (PDB) 2VAG) with meridianin F (yellow), the co-crystallized V25 inhibitor (green), and the best
pose of kororamide A (magenta). Letters and numbers correspond to their position in the amino acid
sequence and the PDB file numbering.
2.3. Marine Natural Products and Indole Scaffold Validation
With the aim of testing the importance of the indole scaffold as structural key feature on the
kinases ATP inhibitors and assuming the well-known Structure Activity Relationship (SAR) principle
(i.e., structurally similar compounds will have similar biological activities) a substructure search was
performed over the MarinLit database, a dataset that includes revised compounds from marine natural
products [44]. In that sense, similar compounds to meridianin F and kororamide A and the indole
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scaffold were searched over this database. A list of 24 compounds was obtained, 18 compounds when
the indole scaffold was used as a seed, and three using meridianin F and kororamide A, respectively.
The list could contain more molecules if all the indole-containing compounds were selected. However,
we decided that this number is adequate to test if the indole scaffold with several, mostly minor,
additions is enough to have a theoretical inhibitory effect over the four kinases, or whether a complex
structure like meridianin F or kororamide A is necessary. Docking calculations were performed to
analyse the binding behaviour of all of them over GSK3β, CK1δ, DYRK1A, and CLK1 (Table 3).
Table 3. Summary of classical rigid docking calculations of the marine natural compounds found
in the MarinLit database after a substructure similarity search using an indole group, meridianin F,
and kororamide A as input molecules. To avoid false positives, each docking calculation was performed
twice (R0/R1). All energies values are kcal/mol.
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 R0/R1 R0/R1 R0/R1 R0/R1  R0/R1 R0/R1 R0/R1 R0/R1 
L17640 −6.4/−6.4 −7.3/−7.3 −7/−7 −6/−6 L4950 −9.1/−9.1 −9.1/−9.1 −9.1/−9.1 −9.1/−9.1 
L1189 −6.8/−6.8 −7.6/−7.6 −7.2/−7.2 −5.9/−5.9 L4949 −8.7/−8.7 −8.7/−8.7 −8.7/−8.7 −8.7/−8.7 
L34 −7.2/−7.2 −8.1/−8.1 −8.2/−8.2 −6.9/−6.9 L4951 −9/−9 −9/−9 −9/−9 −9/−9 
L4080 −6.1/−6.1 −6.9/−6.9 −6.8/−6.8 −6/−6      
L28238 −6.5/−6.5 −7.8/−7.8 −7.3/−7.3 −5.8/−5.8      
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Energy L4081 −6.4/−6.4 −7/−7 −6.8/−6.8 −6.4/−6.4  
L29233 −8.5/−8.5 −8.5/−8.5 −9.3/−9.3 −8.2/−8.2  R0/R1 R0/R1 R0/R1 R0/R1 
L24201 −10.6/−10.6 −8.8/−8.8 −10.4/−10.4 −9.3/−9.3 L9830 −7.4/−7.4 −7.4/−7.4 −7.4/−7.4 −7.4/−7.4 
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The molecules names (Lxxxx) corresponds to the MarineLit entry code per each compound. 
All those compounds with energies higher than −9.0 kcal/mol obtained in at least one of the 
studied targets were considered promising compounds. In fact, after analysing their scaffold, a trend 
can be seen because all of them have three or more aromatic rings and most of them have two indole 
scaffolds (Figure A1). Some interesting kinase inhibitors described in recent years corroborate this 
finding, since they incorporate an indole moiety on their structures [24,25,28,54–56]. 
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All those compounds with energies higher than −9.0 kcal/mol obtained in at least one of the
studied targets were considered promising compounds. In fact, after analysing their scaffold, a trend
can be seen b cause all o em have thr e or mo a om tic rings and most f em have two indole
scaffolds (Figure A1). Some interesting kinase inhibitors described in recent years corroborate this
finding, since they incorporate an indole moiety on their structures [24,25,28,54–56].
Moreover, looking at the top ranked compounds, it is easily observed that all of them have a bromine
(Br) substituent. Actually, all the 24 compounds have at least one Br atom, a differential signature
of marine compounds respect to terrestrial molecules. Many marine organism produce halogenated
metabolites unlike terrestrial species [43]. This corroborates the proposed importance of the indole
scaffold on the kinases inhibition and seems to point out that the combination of an indole scaffold with
halogen substituents could be a good starting point to design new possible inhibitors of the four kinases.
This hypothesis is not an isolated fact as marine compounds with this moiety, different to meridianin F
and kororamide A, have shown inhibitory effects against some of the studied kinases [24,28].
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2.4. Indole Derivatives
As mentioned above the SAR hypothesis, widely used in drug discovery, has the premise that
structurally-similar molecules have similar biological activities and, thus, similar biological targets.
Several known kinase inhibitors possess this moiety and some of them even present a halogenated
version of it. In a previous work, we showed that meridianin F, which has a halogenated indole scaffold
was the more active member of the family, highlighting the role of this moiety. Now, we have observed
that kororamide A and B, given the similarity to meridianin following the SAR principle, could be
possible inhibitors of these kinases. This fact is at least partially confirmed (further experiments are
needed for a complete validation) because of the in silico obtained binding energies over GSK3β,
CK1δ, DYRK1A, and CLK1, reported above. All these facts together, with the observed results in
Table 3, made us hypothesize that starting from an halogenated indole moiety and following structural
features extracted from meridianin F and kororamide A, we could design indole derivatives that could
become kinase inhibitors. Concretely, the indole group was used as a template for the design of a
series of seven analogue compounds with different fragments attached to the R3 position of the indole
(compounds 1–7; Table 4) and substituted with different combinations of halogen atoms at positions
R1 and R2 (a–g combinations; Table 4). Altogether, 49 compounds were designed.
Marine animals have demonstrated to be rich sources of halogenated metabolites and halogenated
compounds have a wide range of biological activities [42]. Most halogenated drugs are fluorine (F),
followed by chlorine (Cl) and bromine (Br). Contrastingly, for marine-derived molecules, rather than
chlorine, the most prevalent halogen found is Br [57]. Halogenated molecules are interesting
therapeutic opportunities and it is estimated that one quarter of the total number of final compounds
synthesized have an insertion that involves halogens [58]. Halogenated ligands lead to more stable
complexes than non-halogenated ligands, and this is important to explain molecular recognition or
to planning a screening study [58,59]. Moreover, the capability of halogen atoms to improve oral
absorption, lipophilicity, blood brain barrier (BBB) permeability, metabolic and chemical stability,
or even potency is well known [58,60]. Therefore, the three mentioned halogen groups at R1 and R2
positions were introduced and evaluated per compound (1–7 + a–g) with the aim of designing the best
possible kinase inhibitors (Table 4).
2.5. In Silico Binding and Binding Mode Analysis of Indole Derivatives
To analyse the feasibility of the designed compounds as kinase inhibitors by an in silico binding
analysis, their binding mode and binding strength against GSK3β, CK1δ, DYRK1A, and CLK1 were
analysed. To start with, docking experiments were performed. A total of 441 poses per target were
obtained from the 49 compounds of the set. Thereafter, the binding behaviour of all the poses was
analysed, showing that the most populated binding region is, as expected, the ATP cavity. With all
these results in hand, best poses per target in terms of binding mode and binding energy were selected
to perform short MD simulations, for post-processing docking results. For some derivatives none pose
was considered for further studies, as the selection of best compounds was carried out considering
not only the binding energy but also the binding mode of each molecule, after an interaction analysis
study. The poses that did not present good interactions were discarded. Finally, 166 simulations
were carried out, corresponding to diverse poses belonging to 45 compounds for GSK3β, 45 for
CLK1, 46 in the case of DYRK1A and 30 for CK1δ. After MD simulations, the binding energies of
the target-ligand complexes were estimated by molecular mechanics/generalized born surface area
(MM/GBSA) calculations. Table 5 summarizes the binding energies of the best indole derivatives,
obtained after MD, per compound (1–7) and target. The rest of the binding energies obtained per
derivative and target are reported at Tables A1–A4, respectively.
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Table 4. From meridianin F and kororamide A, the indole scaffold was selected to derive new compounds.
More precisely, seven indole derivatives were designed (compound 1–7). The R3 position was fulfilled
with diverse structural elements mainly inspired on meridianin and kororamide structures. Compound 1
with a ketone group, compound 2 with an aromatic ring, compound 3 with a methylamine, compound
4 with a methyl group, compound 5 with methanol, compound 6 with an ethylamine and compound 7
with an ethyl-methylamine. The R1 and R2 positions were completed with the permutation of Br, Cl and
F halogen atoms (a–g) over both positions. At the end 49 indole analogue compounds were designed.
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As a general result, we observe that all the evaluated compounds present better binding interaction
energies against CK1δ, DYRK1A and CLK1 than GSK3β, as observed for meridianins [37]. Additionally,
as a general trend, compound 1 and 2 always show better energies than the rest of derivatives,
highlighting that the fragments introduced in the pyrrole ring (a ketone and an aromatic ring,
respectively) of the indole scaffold at R3 position could have beneficial effects to achieve better
inhibitory activities over the ATP-binding site of the four studied kinases. Finally, it must be remarked
that the designed compounds that do not work against the kinases are different for each one of them,
thus opening the door for exploiting these differences in the future to gain selectivity over the four
analysed kinases.
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Table 5. Summary of molecular mechanics/generalized born surface area (MM/GBSA) calculations
of the best derived analogues over the four targets studied. Lowercase letters indicate the halogen
substituent group (a–g), as described in Table 4.
GSK3β CK1δ DYRK1A CLK1
Binding Energy Binding Energy Binding Energy Binding Energy
Compound 1 a −30.3141 a −35.4499 e −32.8862 g −30.3541
Compound 2 a −31.2458 e −37.8982 a −37.8422 a −34.1041
Compound 3 a −13.8779 g −28.7631 a −15.2733 f −20.4786
Compound 4 a −27.6481 e −28.6573 a −30.7518 e −28.3695
Compound 5 a −27.6534 e −28.5831 a −31.2535 c −29.4190
Compound 6 a −18.5779 a −26.4630 a −18.9387 g −30.7737
Compound 7 a −18.8955 a −18.4901 a −20.8203 g −25.4765
All energies values are kcal/mol. Maeridianin F results come from our previus publication [37].
2.5.1. GSK3β
As said, the best docked complexes were selected to perform further analysis. For GSK3β 75 poses
were chosen and over them MD simulations were performed. From the total studied set, and with the
aim of analysing the diverse derivatives, the best a–g combination for each of the 1–7 compounds per
target was selected. Over the seven best compounds found after MD simulations in terms of binding
energy, further analyses were performed, extracting some interesting features. Focusing on the halogen
substituents, the best compounds are always those that contain two Br atoms at R1 and R2 position,
reflecting the importance of Br substituents observed in previous studies [24,37].
A general pattern regarding the interactions performed by each of the seven best derived
compounds at the catalytic ATP binding site was observed. In general, I62, V70, A83, V110, L132,
D133, Y134, V135, Y138, and L188 are the most important amino acids for their stabilization over
the ATP catalytic pocket (Figure 4). The NH indole group is essential to establish hydrogen bond
interactions with the carboxylic acid group (deprotonated under biological conditions) of D133 and/or
V135. AR, described by LDYV motif, accommodates the seven best compounds, all of them showing
the same binding mode/pose, stabilized by hydrophobic contacts. The indole group is wrapped
by N-terminal I62 and V70 residues found near the GRR, together with A83 placed at the HP and
C-terminal residues V110 and L188 present at the SP. As the binding mode analysis reveals, all the
compounds have the same binding mode, thus binding energy results and MD simulations were used
with the aim of identifying some differential features among them. MD analysis reveals that the indole
scaffold is maintained wrapped in the same position during all the simulation while the fragments
introduced at R3 are more flexible. A binding energy analysis showed that compound 2a has a slightly
better energy than compound 1a, although both could be considered good plausible options, as the
binding energy differences are around 1 kcal/mol, which seems to point out compound 2a as the best
possible inhibitor.
Looking at the literature, our results show that the binding mode displayed by most of the
analysed compounds, specially by compound 2a, correlates with the binding mode of known inhibitors,
and also that the residues involved on it are key binders [35,61].
2.5.2. CK1δ
For CK1δ, 97 docking poses were subjected to MD simulations. Thereafter, the seven best
compounds, in terms of binding energy were selected to be further analysed. Differently to GSK3β,
there is not a common binding mode shared by the 7 derived analogues and there is not a specific
location of the halogens in the ATP binding site, which can be inferred from the observed binding
modes. Although a general pattern could not be observed, there are common features between the
studied derivatives than can be highlighted. There is a common behaviour between compounds 1,
6, and 7, and compounds 2, 4, and 5 (Figure 5). For the first group the best halogen composition is
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Br-Br (compound 1a, compound 6a and compound 7a), whereas for the second group, the best halogen
composition is e (Br-Cl), while for compound 3, which behaves differently to the rest of the compounds,
is g (Cl-Br). In all compounds a Br atom is present, which seems to indicate that this presence could be
important to increase the binding strength. In general, with few exceptions, the worst binding energies
are obtained when there is no Br atom present. This trend is also observed on the rest of kinases
(Tables A1–A4). In addition, an accurate analysis of the most important residues involved on the seven
compounds binding mode, was performed. This analysis reveals that despite each compound has a
different binding pose, there are conserved interactions at the ATP catalytic cavity. According to that,
the most important residues on the binding of the seven compounds to CLK1δ are I23, A36, Y56, L84,
I148, and D149. All seven derivatives are placed between the HP defined by A36 and the residue I23
that is placed near the GRR, both zones located at the N-terminal region and L84, I149, and D149 placed
at the AR and PBP at the C-terminal domain. All the interactions observed between the analogues and
the residues are mainly hydrophobic contacts. Binding energies reveal that compound 2e (Br-Cl) seems
to be a slightly better inhibitor than compound 1a, although both can be considered good options as
the energy differences are around 2 kcal/mol.
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Different studies have been addressed to find novel and potent CK1δ inhibitors in the last years.
Looking at them, it is easy to observe that the interactions made by of all these molecules are aligned,
validating it, with the binding mode of our proposed derivates [27,32,33,36].
2.5.3. DYRK1A
For DYRK1A, 72 docking poses were selected for further analysis. MD simulations were
performed over all of them, and thereafter the best compound per target, as for the rest of kinases,
was selected. Despite the indole derivatives tested do not shown a shared binding mode as GSK3β,
it is more conserved than for CK1δ. All compounds, except compound 3 that is oriented right upside
down and moreover shows the worst binding energy, shared the same placement at the ATP catalytic
pocket (Figure 6). Analysing the halogen composition of the best compounds it is observed that Br-Br,
at R1–R2 positions, is the most common substituent; only compound 1 has a different combination
(Br-Cl). As a general conclusion, as with the other three kinases, the presence of at least one Br atom is
important to have a good binding affinity.Mar. Drugs 2018, 16, x 14 of 33 
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2.5.4. CLK1
For CLK1, 87 docking poses were selected for further analysis. All of them were subjected to
MD simulations selecting then the best one per target. A first binding mode observation reveals that
a common binding mode was found for compounds 1, 2, and 6 (Figure 7). These three compounds
have the best binding energy, and this could point out the importance of R1, R2 and R3 substituents to
gain inhibitory capacity. Compound 3, despite having a similar binding pose, does not show good
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energies. The other compounds (4, 5, and 7) show slightly lower binding energies and a different
binding mode, even between them. Focused on the halogen groups, in this target there is not a clear
trend, as the seven best compounds show five different halogen substituents (a, c, e, f, and g). Despite
this fact, not observed in the rest of studied kinases, a similar trend can be seen. Most of the seven top
compounds have a Br atom, except compound 5c. Moreover, in agreement with the rest of compounds
the seven top derivatives are mainly Br or Cl substituents on R1 or R2 position, with the exception
of compound 3f. This seems to suggest that, as for the other targets, all of the analysed halogen
substituents combinations could give good inhibitory results, but the presence of a Br is a key factor.
In fact, for this target, as seen for the other kinases, the compound 2a is the best one in terms of
binding energy.Mar. Drugs 2018, 16, x 15 of 33 
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in particular F241 and L244. n the -ter inal region, residues E292 and L295 at the SP and 324
placed at PBP are the ost important amino acids to stabilize the derived compounds over CLK1.
As compound 2a, the other best compounds tend to point their halogen groups between the AR and
the HP, fact that facilitate residues as F175 placed at the GRR and E292 or L295 placed at the opposite
SP, surround and fixed the indole scaffolds. Interestingly, the binding mode exposed here for the
derived analogues in general, and also for the best compound, 2a, in particular, is validated by other
inhibitors reported in the literature [30,31].
The in silico binding studies performed over the four kinases indicate that the derivatives coming
fro compound 2, 2a and 2e, located at the middle of the ATP binding cavity, seem to be the most
plausible ATP competitive inhibitor. However, other derivatives, especially for compound 1 should
not be discarded. In general, the presence of the benzene ring at position R3 could have a more
positive influence on compounds stabilization at the catalytic site than other substituents. Looking
at the literature, several inhibitors described for GSK3β, CK1δ, DYRK1A, and CLK1, as well as
other members of the protein kinase family, have aromatic rings in the terminal positio s. Moreover,
the analysis of the effect of the halogen groups used as substituents at R1 and R2 positions pointed
out that its presence can influence the binding strength of the complex (ligand-target). In general, if at
least one of the substituents is a Br atom the binding energy is better. An interesting trend found here
is that Br seems to be the “best” halogen followed by Cl and F, which, in general, gives worst binding
energies. This finding is in line with what is observed in nature, since natural halogenated indole
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alkaloids contain mostly bromine and chlorine, being the iodinated and fluorinated compounds less
abundant [43].
2.6. Selectivity
One of the most important challenges on the design of novel kinase inhibitors is the lack of
selectivity over the ATP binding site, which is critical in clinical effectiveness of most dugs [46,48].
Most kinase small-molecule inhibitors bind to the ATP catalytic cavity near the AR and wrapped
by GRR and HP on the T-lobe and SP and PBP at the C-lobe. The herein performed study does not
reveal any significative selectivity over the four kinases for any of the analysed compounds, which
could be easily observed looking at the obtained binding modes and energies. However, analysing the
residues involved on the binding and the regions occupied by the analogues, some interesting trends
that could be exploited in the future can be observed. Interestingly, regarding the binding modes,
the best binding energies were obtained on those compounds that are (partially) placed at the PBP.
This region, that is very exposed to the solvent and is not usually exploited to gain binding affinity,
can be useful to improve the inhibitors selectivity since it contains non-conserved amino acids [46].
Regarding the binding energy results per se, without having into account the binding mode,
remarkable significant differences are not observed. The best compound for each target (2a and 2e
respectively) comes from the same scaffold, compound 2a being the best theoretical inhibitor for three
of the four targets. If we analyse the binding energies of these top compounds, compounds 2a and
2e over DYRK1A and CK1δ, respectively, show a better interaction energy, around 6 kcal/mol of
difference, respect to the binding energy of compound 2a over GSK3β and 3 kcal/mol over CLK1.
However, although a slight preference could be inferred from this, the binding of these four compounds
to all the four targets is possible with a reasonably good strength. In general, the main differences are
observed between the derived compounds 2 (mainly) and 1, which seems to have better energies than
those molecules coming from analogues 3 to 6, and especially with respect to the molecules coming
from analogue compound 7 (Table 5). For GSK3β the best compounds coming from derivatives from 2
and 1 (1 kcal/mol of difference between them) are displaying the best interaction energies, followed
by those from analogues 4 and 5 (around 4 kcal/mol of difference to compound 2a), and finally the
worst compounds come from analogues 3, 6, and 7 with differences around 13 to 17 kcal/mol respect
compound 2a. In the case of CK1δ, as for GSK3β, the top ranked compounds from analogues 2 and 1
(1.5 kcal/mol of difference between them) have the best binding energies, followed by those from
analogues 3–6 with differences around 9 to 11 kcal/mol with respect to compound 2e, and finally
compound 7a with a difference of around 19 kcal/mol with respect to 2e. For DYRK1A, the best from
compound 2 is the top molecule in terms of interaction energy. Compound 1a shows a difference of
around 5 kcal/mol, whereas compounds 4 and 5 present differences between 6.5 and 7 kcal/mol,
respectively, and compounds coming from scaffolds 3, 6, and 7 between 17 and 22.5 kcal/mol. In the
case of CLK1, compound 2a has the better binding energies, followed by those from analogues 1 and 6
(differences around 3 kcal/mol), molecules derived from compounds 4 and 5 (differences around
5 kcal/mol), and finally those from analogues 3 and 7, that show differences around 8.5 to 13 kcal/mol
respect to the binding energy
Looking to the 1–7 compounds per target, it can be observed that for compounds 4 and 5 the
binding energy differences between the top a–g derivatives range between 2 and 4 kcal/mol between
the four kinases. For compounds 1, 2, and 7 the differences are higher, ranging between 2.5 and
7 kcal/mol, depending on the compound and target. Finally, for compounds derived from analogues
3 and 6 the differences are even higher, ranging between 8 and 15, and 4 and 12 kcal/mol, respectively.
In general, there is not any noticeable selectivity trend derived from the binding energy, although there
are some features that could be further exploited. For instance, for DYRK1A and CLK1 an aromatic
ring at R3 position is the best choice to gain activity over them, whereas for GSK3β and CK1δ a ketone
group at this position could also work, enhancing a way to design selective compounds at least for
some of the four kinases.
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Exploring the effect of the halogen atoms over the binding strength, as said above, some general
trends could be observed but again, its presence does not give any clearly marked or significant
selectivity trend between targets. The presence of Br atoms seems to increase the binding strength
more than the presence of Cl of F, being in general Cl “better” than F to get good energetic results.
However, a possible selectivity feature could be observed due to compound 2e. Docking energy
results are similar for the four kinases, but it only performs good interactions for CK1δ. This is the
reason why MD simulation over this compound was only performed in complex with it, while for
the other three kinases it was not selected. Compound 2a gave good docking energies for all four
targets but performed good interactions only with GSK3β, DYRK1A and CLK1, so the fact of having
a Br-Cl combination at R1-R2 plus an aromatic ring at R3 could be a sign of selectivity over CK1δ,
although it should be further explored, as other Cl combinations give good results for the other kinases
(Tables A1–A4).
2.7. 2a and 2e Unbinding
To reinforce and validate the observed binding trends, as well as to find a differential feature
that could help to enhance the selectivity of future derived compounds over the four kinases, steered
molecular dynamics (SMD) simulations were performed. Since at the energy and binding mode level
there are no significant differences, we intended to see if there was some type of selectivity derived
from the protein structure that influences the facility/difficulty of unbinding of the most promising
inhibitory compounds 2a and 2e per target (Figure 8).
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At the beginning of each simulation (t = 0), the compound is in the bound state, placed inside the
ATP cavity interacting with the residues previously described. After one nanosecond (ns), at the four
kinases, the ligand is completely out of the cavity. In the case of GSK3β (Figure 6A) a force of around
400 pN (piconewtons) is needed to extract compound 2a from its catalytic cavity. The compound
dissociation from the target take place at 200 femtoseconds (fs), moment where the force decrease
approach zero pN which means that the compound is out of the cavity. For CK1δ (Figure 7B) that
hosts the best compound in terms of binding energy, 2e, the necessary force to break the ligand-target
complex is higher than for the GSK3β complex, with forces that reach up to 600 pN. The ligand
unbinding takes place at a similar time than for GSK3β complex, around 200 ps although it takes
slightly more time. The dissociation of compound 2a from DYRK1A (Figure 7C) is done in two phases.
A primary rupture force seems to occur before 100 fs, and immediately afterwards it could be observed
the highest energy point (around 500 pN), corresponding to the second break. A visual inspection
of the SMD confirmed that at this moment, the compound is still inside the ATP pocket. Over 200 fs,
the force, after a progressive decrease, arrives to zero pN. This progressive decline correlates with the
progressive loose of interactions during the way out of the compound from the catalytic cavity. For the
CLK1-compound 2a complex (Figure 7C) a similar situation is observed. A primary rupture around
100 fs, moment in that, as for DYRK1A, the compound is still placed at the ATP binding site and it is not
until later, at 200 fs, when a sudden drop in the energy can be observed, indicating the completely loss
of interactions and therefore, the leaving of the cavity. As a general trend, around 200 ps compounds
2a and 2e leave the catalytic pocket of the different kinases, requiring a different amount of force that
is in line with the observed binding energy. Usually, the better the binding energy, the higher the
force needed to break the complex and the longer the residence time. In that sense, the SMD results
corroborate what has been seen so far: CK1δ- 2e and DYRK1A-compound 2a complexes that have
the higher binding energies also seem to have (slightly) longer residence times and require a higher
force to take out their respective ligands from their catalytic pockets. There is not any feature that
suggests a selectivity trend derived from the unbinding process that could not be extracted from the
binding energy results. Compound 2a is more selective (it binds stronger and requires a higher effort
to remove it) for DYRK1A than for GSK3β and CLK1 but could bind to all of them. Compound 2e
seems to be more difficult to unbind that compound 2a, but this correlates with the higher binding
energy it shows after MD.
2.8. Pharmacokinetic Properties of Kororamide A–B, Convolutamine I–J, and the Designed Derivatives
Due to the importance of pharmacokinetics (PK) and its impact on drug discovery process,
convolutamine I–J, kororamide A–B and the whole set of 49 analogues compounds were analysed,
studying their ADME/Tox features. The PK properties of the two best derived compounds 2a and
2e are summarized on Tables 6 and 7. The full set of derivates were also analysed and results can be
found at Table A5 (absorption and distribution) and Table A6 (metabolism, excretion and toxicity).
Table 6. Summary of absorption and distribution properties of the two best compounds 2a and 2e
found on the four studied kinases. BBB: blood brain barrier, PPB: protein-protein binding, VDss: steady
state volume of distribution, CNS: central nervous system.
Absorption Distribution




Absorption LogP BBB PPB VDss
CNS
Permeability
Compound 2a 351 −6.1 inactive Moderate 90.067 4.1 0.477 High 0.234 −0.894
Compound 2e 290.1 −5.7 inactive Moderate 91.036 3.8 0.508 High 0.076 −0.92
The first PK property analysed was molecular weight, and all compounds show values under
500 Dalton (Da). The higher molecular mass was found for compound 2a with 351 Da, which is in good
agreement with the sizes that a small therapeutic molecule that should cross the BBB should have.
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Table 7. Summary of metabolism, excretion and toxicity properties of the two best compounds 2a and
2e found on the four studied kinases. CYP: cytochrome, OCT2: organic cation transporter 2, hERG:
human ether-a-go-go gene, MRTD: maximum recommended tolerated dose.
Metabolism Excretion Toxicity
Compound CYP450 OCT2 Substrate hERG MRTD AMES Toxicity Hepatotoxicity
Compound 2a Yes No <4.0 0.673 Yes No
Compound 2e Yes No <4.0 0.641 Yes No
2.8.1. Absorption Properties
Absorption describes the process by which drug candidates move from the point of administration
to the blood. LogS descriptor confirmed good solubility in water and good bioavailability for each
compound. The derivatives coming from compounds 2 show values that are between −5.1 and
−6.1, while for the rest of the derivatives, values are between −3 and −4. Caco-2 permeability
revealed medium to high values for all the compounds, except for kororamide A, which was
low. The compounds that have a benzene at R3 position as well as the derivatives with F at R1
and R2 positions show moderate permeability and should be optimized in the future. Regarding
P-glycoprotein (Pgp) binding, no compound was predicted to act over it. The interaction with
Pgp has many pharmacological implications that could result in pharmaceutical advantages or
contraindications. For instance, Pgp modulation has been suggested as a mechanism to improve
CNS pharmacotherapy [62–65], but none of the derivatives here seem to have this ability. On the
other hand, intestinal absorption values higher than 30% are considered well-absorbed compounds,
and for the entire set obtained values are higher than 89%. All of these absorption results suggest good
absorption properties for the 49 designed derivatives, plus kororamides and convolutamines.
2.8.2. Distribution Properties
Distribution describes the migration of a compound from the circulation to the extravascular
system. LogP values lower than 5 indicate that the compounds have an appropriate hydrophobicity
and permeability. In that sense, the derivatives coming from compound 2, as well as convolutamine
J and kororamide A have the highest values (≈4) while the rest of compounds are between 2 and 3.
Opposite to LogP behaviour, plasma-protein binding (PPB) and steady state volume of distribution
(VDss) are not showing as good tendencies for the best derivatives compounds coming from scaffold
1 and 2, and Convolutamine J. Most of the analysed molecules showed medium to high PBP values
(except kororamide A and compounds 3b, 5b, 6b, and 7b with low PPB values) indicating that a high
percentage of the administrated compound will be found attached to proteins, affecting its diffusion
and its efficiency. As less bound a drug is to plasma proteins, the more efficient it is, as it can traverse
cell membranes or diffuse. Regarding VDss, derivatives from scaffolds 3, 6, and 7 and convolutamine
I–J plus kororamide A, have high VDss values (>0.45), while for the rest of compounds, its distribution
is low to medium, in a close agreement with PBP results. BBB descriptors with results higher than
>0.3 reveals good distribution to the brain, as they could pass the blood brain barrier. The highest
values are found for convolutamine I, kororamide A, and the derivatives coming from scaffolds 2 and
4, as well as for compounds 5b and 7b. However, it should be considered that most of the compounds
not predicted to cross BBB have values near the threshold. In addition to BBB, Central nervous system
(CNS) permeability was measured. This measure seems to be more precise than BBB, as it is a more
direct measurement [66]. Kororamides and convolutamines do not show good permeability values,
whereas all the derived compounds showed good results (> −2) allowing us to consider that most of
the designed compounds could penetrate the CNS, specially the compounds coming from scaffolds
2 and 4, among which there are the two best candidates 2a and 2e.
Mar. Drugs 2018, 16, 386 19 of 32
2.8.3. Metabolism Properties
Cytochrome (CYP) P450 is an important enzyme used to predict drug metabolism. Many drugs
could be deactivated or activated by CYP450, as cytochrome P450 enzymes that can be inhibited or
induced by drugs, resulting in clinically significant drug-drug interactions that can cause unanticipated
adverse reactions or therapeutic failures. Our results revealed that all the analysed compounds,
except kororamide B, are likely to be metabolised by CYP450, so their properties should be carefully
analysed to design lead compounds from the herein-studied molecules [67,68].
2.8.4. Excretion Properties
Regarding excretion properties, describing the transport of drugs into the urine or bile,
good results were obtained. It was found that only kororamide A and B tend to act as a substrate of the
organic cation transporter 2 (OCT2 or Solute carrier family 22 member 2, SLC22A2), which means that,
in general, and for the two best derivatives 2a and 2e, non-clearance problems and adverse interactions
with co-administrated OCT2 inhibitors are expected.
2.8.5. Toxicity Properties
During drug development, safety is always the most important issue, including a variety of
toxicities and adverse drug effects that should be evaluated in preclinical and clinical trial phases [69].
Between the measured properties, the inhibition of the potassium channels encoded by the human
ether-a-go-go gene (hERG) is basic. Our results indicate that none of the compounds seem to be toxic
due to hERG. In the same way, none of the designed derivatives is susceptible to be hepatotoxic.
However, convolutamine I and J as well as kororamide A tend to be hepatotoxic. Looking at AMES
toxicity, which predicts mutagenic and carcinogenic properties, our results revealed that the derivatives
from compound 2, as the top derivatives 2a and 2e, and kororamide B are predicted to be toxic,
while the rest of the set does not. Regarding the maximum recommended tolerated dose (MRTD),
the four brominated alkaloids as well as compounds coming from scaffolds 3, 6 and 7 showed
low values/doses, which is not the best scenario, whereas the rest of the compounds present good
MRTD values.
The well-known Lipinski’s rule of five, formulated in 1997 and that remains in force [70] was
also used in combination with the different ADME/Tox properties described above with the aim of
evaluate/determine druglikeness of the analysed compounds. To assess how druglike a substance is
based on Lipinski’s rules it is accepted that it should have (1) not more than five hydrogen bond donors,
(2) ten hydrogen bond acceptors, (3) a molecular mass less than 500 Da, and (4) a LogP not greater than
5. Focusing on the two best compounds (2a and 2e), both have one hydrogen donor and no acceptors.
Additionally, as seen in Tables 6 and 7, the other Lipinski requirements are met. Thus, taking into
consideration all the ADMET results described previously, these two compounds can be proposed as
good hit candidates, having into account that some properties, such as the possible carcinogenesis and
mutagenesis problems should be carefully addressed. In fact, absorption, distribution metabolism,
excretion, and toxicity properties should be more or less improved for all the designed compounds,
in a further hit to lead (H2L) optimization process. Toxicity should be removed, and compounds
interaction with cytochrome P450 carefully analysed and, given the case, eliminated or modulated.
Moreover, Caco-2 permeability could be increased, as well as their distribution properties should be
improved, lowering the PPB and VDss, to be able to diffuse and penetrate into cells easily.
3. Materials and Methods
3.1. Computational Virtual Screening
It is well known that there is a correlation between (chemical) structure and (biological) activity,
the structure activity relationship (SAR). This SAR is widely exploited in many aspects of the
drug discovery pipeline, ranging from compound screening to lead optimization processes, at the
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experimental and computational levels. Herein, we have performed a 2D virtual screening search
over the MarinLit database using its substructure search functionality. Using as an input meridianin
F and kororamide A (the two indole compounds that have shown a better binding strength against
the four analysed kinases), as well as the indole scaffold alone, a similarity search was performed
over MarinLit, obtaining a list of compounds having an indole scaffold in their structure and/or are
structurally similar to meridianin F and/or kororamide A. The name and structure of the similar
compounds can be found in Figure A1.
3.2. Structure Modelling
Convolutamine J, I, and kororamide A and B, were modelled from Dashti et al. [38]. Ligands were
prepared to generate energetically-minimized three dimensional (3D) coordinates.
To perform computational work, obtaining good structures to start with is crucial, so prior to any
calculation, good computational models should be constructed. The structures of the analysed targets
were modelled from 3D crystal structures obtained from the Protein Data Bank (RCSB PDB) [71].
Those structures represented human targets and are the best structures in terms of sequence coverage,
of the whole target, in general, and of the binding pocket of each target, in particular. Since all the
four kinases biological assembly is in monomeric forms, GSK3β and CK1δ chain B and DYRK1A
and CLK1 chain A were respectively selected to perform further studies. To do so, due to the fact
that the four studied targets have 3D crystallographic structures, the ATP competitive inhibitor
OS1 was co-crystallized with GSK3β (PDB: 3PUP) [35], 1QG was co-crystallized with CK1δ (PDB:
4KBK) [36], the crystal structures of DYRK1A was complexed with 3RA (PDB: 4AZE) [26] and, finally,
V25 was co-crystallized with CLK1 (PDB: 2VAG) [31] and used as a template to perform rigid docking
calculations using Itzamna (Mind the Byte.SL, Barcelona, Spain) [72].
3.3. Docking Calculations
Docking calculations can identify small molecules (ligands) that fit well into the putative binding
pocket of a given protein (target) in an optimal way. Without any other specification, generally speaking,
docking refers to classical (rigid) docking where only the movement of the ligand is allowed [73].
This kind of calculation allows to elucidate the binding mode, as well as the binding strength of the
analysed molecules. Moreover, the molecules could be ranked according to their binding energy.
However, this static model is far from real, because proteins are dynamic entities that, to carry out
any biological function, need to move. Thus, this movement should be taken into account to obtain
good predictions that could be compared with experiments [74,75]. A good option to take the protein
movement into account is post-processing docking results by MD simulations [76,77]. MD simulations
used to improve docking prediction as they allow observing the induced fit events or, in other words,
the conformational adaptation of the target to the ligand, not only the ligand adaptation as happens
with rigid docking experiments. Moreover, the stability of the docked complex could be analysed
using this pipeline [74,77].
All docking calculations were performed using Itzamna software (Mind the Byte.SL, Barcelona,
Spain) [72]. Docking studies were performed between kororamide A–B, convolutamine I–J. and the
set of 49 derived compounds against GSK3β, CK1δ, DYRK1A, and CLK1. Two runs were carried out
for each calculation to avoid false positives. As the used 3D crystal structures of the kinases were
co-crystallized with a ligand, this cavity was employed to dock the analysed compounds for each of
the four targets.
3.4. Molecular Dynamics Simulations
MD simulations are able to capture the dynamic nature of proteins and bimolecular systems,
in general. Herein, short (1 ns) MD simulations were performed using the NAMD program, version
2.11, over the best ligand-target complexes (the top ranked compounds according to the docking
binding energies) [78]. The Amber ff99SB-ILDN and the General Amber Force Field (GAFF) set of
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parameters were employed for modelling receptors and ligands, respectively [79,80], as both forcefields
have been extensively tested and used in protein-ligand complexes, giving satisfactory results in several
studies [79–82]. An antechamber was employed to calculate the ligand GAFF parameters and the
leap module of Amber Tools to obtain the parameters of the proteins [83,84]. Explicit solvent MD
simulations were carried out using a time-step of 2 fs and a TIP3P water model imposing periodic
boundary conditions via a cubic box [85]. The distance between the complex and the edge of the box
was set to 10 Å. The particle-mesh Ewald method was used to calculate the electrostatic interactions.
The temperate and the pressure were kept constant at 300 K and 1 atm, respectively, using Langevin
dynamics and a Langevin piston barostat. Bond lengths to hydrogens were constrained with the
SHAKE algorithm [86]. Before starting the production simulation, all position restraints were removed,
the system was firstly submitted to an energy minimization, following by a solvent equilibration (using
harmonic position restraints on the heavy atoms of the protein-ligand complex) and, finally, to a slow
heating-up, from 0 to 300 K.
3.5. Molecular Mechanics/Generalized Born Surface Area
After performing MD simulations to estimate the ∆G binding free energy of ligand-target
complexes, Molecular Mechanics Generalized Born Surface Area continuum solvation (MM/GBSA)
reweighting techniques were employed [87]. These techniques outperform docking results because
they are employed after MD, thus taking into account the dynamic behaviour of the protein-ligand
complexes. However, it should be highlighted that although improve docking binding energy
values, are far to be experimentally comparable. Herein, like in other studies, we applied
MM/GBSA reweighting techniques over the generated MD trajectories for post-processing docking
results [77,88,89]. The MD generated trajectories were employed as input of the MM/GBSA calculations
that were realized using the MMPBSA Python algorithm contained within the Amber Tools suite [89].
3.6. Steered Molecular Dynamics
Steered molecular dynamics (SMD) is a simulation tool used to explore processes, which cannot
usually be achieved by standard MD simulation, such as ligand-protein unbinding or certain protein
conformational charges. Here, we have employed it to study ligand unbinding processes. In that sense,
in SMD simulations, a time-dependent external force is applied to the ligand, from an internal atom
of the protein, to facilitate its unbinding. For a given ligand bound to a target, it allows establishing
a theoretical correlation between unbinding forces and residence time and, in turn, its inhibitory
capacity; the larger the force and time needed to unbind a ligand from a receptor the higher its binding
affinity [90–93].
SMD simulations were performed using NAMD version 2.11 [78]. Compounds 2a and 2e over
GSK3β, DYRK1A, CLK1, and CK1δ, respectively, were performed. The last frame obtained from
the postprocessing MD simulations was used as an input. A harmonic constraint force constant
of 4 kcal/mol/Å with a constant velocity of 0.00002 Å/ns was applied. The time length for each
simulation was 1 ns, using a time-step of 2 fs, which was enough to observe the entire ligand unbinding
process. The rest of the parameters of the simulations were the same employed for MD simulations.
The generated trajectory was finally analysed using visual molecular dynamics (VMD) to extract the
exerted force (pN) per simulation frame [94].
3.7. Interaction Analysis
To analyse the key residues of the binding pocket involved in the ligand binding, we deeply
analysed the obtained binding modes after docking and MD simulations, comparing the obtained
results against “known binders” of each of the targets. The “known binders” are important residues for
the interaction of reported substrates/inhibitors and were identified at the literature [25–27,30–36,61]
as well as in an in-house, recently-constructed database. It was built by crossing ChEMBL and the
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PDB [62], and it is composed of all PDB structures per UniProt ID with active compounds, plus the
residues with which they interact [95,96].
3.8. ADME/Tox Properties Prediction
ADME/Tox estimation of the analysed compounds was performed using machine-learning (ML)
models. These models were enclosed within the ADMETer software tool (Mind the Byte.SL, Barcelona,
Spain) and the pkCSM webserver, respectively [66,97]. Concretely, molecular weight, MRTD, logS,
logP, Pgp, caco-2 permeability, BBB penetration, PPB, VDss, CNS penetration, intestinal absorption,
AMES toxicity, CYP450 metabolism, hepatotoxicity, hERG binding, and OCT2 binding were predicted.
A PgP models were generated by Random Forest against Poongavanam and co-workers (Pgp) and
Sedykh et al. datasets [98,99]. The other models and the datasets against the models that were
generated are further explained by Llorach-Pares et al. and Pires and co-workers, respectively [37,66].
3.9. Graphical Representations
Graphical representations of protein-ligand complexes were prepared using PyMOL version 1.7
and PLIP version 1.3.3 [100,101]. 2D ligand images were prepared using the RDKit [102] Python library
and SMD plots using matplotlib [103] and seaborn [104] Python libraries.
4. Conclusions
Kororamide A–B and convolutamine I–J can act as tau (GSK3β and CK1δ) and dual-specificity
(DYRK1A and CLK1) protein kinase inhibitors. Kororamide A–B are brominated indole alkaloids
structurally very similar to meridianins. Only taking this fact into account and following the SAR
principle could a kororamides kinase inhibitory effect be hypothesized. Therefore, the in silico binding
results we obtained were expected. These results corroborate the idea of that kororamides could be
kinase inhibitors with a therapeutic role in AD. Convolutamine I–J, which are not structurally similar
to meridianins or kororamides, but are brominated heterocyclic compounds like other known kinase
inhibitors, have also shown a plausible inhibitory capacity over GSK3β, CK1δ, DYRK1A, and CLK1.
Altogether, the results highlight the role of the indole scaffold and the halogen substituents on these
kinase inhibitions, being common features among all the compounds.
However, as happened with several other compounds acting over kinases, their main problem is
the selectivity. These compounds seem to be somehow selective for one of the kinases, and it is clear
which kinase is the preferred one to bind and which one is undesired but, in general, the obtained
energy differences are not enough to consider that these compounds are selective. Moreover, the four
brominated alkaloids should be optimized according to their ADMET properties. They have moderated
good absorption properties, but caco-2 permeability could be increased, especially for kororamide
A, as well as the distribution properties. Additionally, the four compounds show a tendency to have
toxicity problems that should be carefully revised, in the same way as compounds interacted with
cytochrome P450, although kororamide B does not show this cytochrome interaction.
Through the inclusion of convolutamine into the analysis (as they are brominated but not indole
compounds), as well as the exploration of some indole-containing compounds from the MarinLit
database, we intended to disentangle whether the indole or the halogen substituents presence is the
most important feature to gain activity over the four kinases studied. However, the main conclusion
extracted is that, individually, both are equally important, and probably the best way to profit from
both features is combining them into halogenated indole scaffolds.
Natural products possess very large therapeutic potential, as reported here and in the related
literature. Within natural products, those of unexplored marine origin are of great interest in the
discovery of novel chemical structures, since they harbour most of the biodiversity of the world [40,105].
Life started in the oceans and many organisms live only there. Due to this, they should be successfully
exploited in the future using sustainability criteria and respecting biodiversity. All this makes
computational CADD contributions very relevant, since no biological sample is needed to perform
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an in silico analysis [106–109]. Taking all of these facts into account, and profiting from the scaffolds
showed by meridianins and kororamides (examples of the importance of halogenated indole scaffolds
to gain kinase inhibitory activity), we designed 49 marine natural product derivatives. Concretely,
we performed a detailed computational study for the development of specific tau (GSK3β and CK1δ)
and dual-specificity (DYRK1A and CLK1) protein kinase inhibitors, starting from marine natural
products, meridianin F and kororamide A, until achieving the rational design of indole scaffolds
derivates as possible ATP-competitive kinase inhibitors for the treatment of AD. We illustrated how
the indole derivate compounds derived from scaffold 2 (an indole with an aromatic ring at R3 position
and halogen substituents at R1 and R2), in general, and compounds 2a and 2e, in particular, could be
proposed as good hit compounds to start an H2L optimization process. Altogether, it could be
concluded that kororamides, especially A, convolutamines, especially J, and compounds 2a and 2e
could be possible ATP-competitive inhibitors against GSK3β, CK1δ, DYRK1A, and CLK1. These results
come from in silico experiments and further in vitro and in vivo studies are required. Our results
constitute a promising starting point for the development of novel anti-AD drugs.
Author Contributions: M.S.-M., L.L.-P. and C.A. conceived the study and designed the experiments. L.L.-P.
carried out the experiments, whereas A.N.-C., C.A. and M.S.-M. supervised them. All the authors analysed and
discussed the results as well as wrote the manuscript.
Funding: This research was partially funded by an Industrial Doctorate grant from the Generalitat of Catalonia to
L.L.-P. (DI 2016-051).
Conflicts of Interest: The authors declare no conflict of interest.
Appendix
Mar. Drugs 2018, 16, x 24 of 33 
 
required. Our results constitute a promising starting point for the development of novel anti-AD 
drugs. 
Author Contributions: M.S.-M., L.L.-P. and C.A. conceived the study and designed the experiments. L.L.-P. 
carried out the experiments, whereas A.N.-C., C.A. and M.S.-M. supervised them. All the authors analysed and 
discussed the results as well as wrote the manuscript. 
Funding: This research was partially funded by an Industrial Doctorate grant from the Generalitat of Catalonia 
to L.L.-P. (DI 2016-051). 
flicts of Interest: The authors declare no conflict of interest. 
ppendix A 
 
Figure A1. Structures of the 24 compounds found at MarinLit database after a similarity based 
substructure search using meridianin F, kororamide A, and the indole scaffold as a seed. 
Table A1. Summary of classical rigid docking calculations of the derived analogues compound set 
over the GSK3β and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculations 
of the best posed analogue compounds. Lowercase letters represent the employed halogen group (a–
g). 
   GSK3β 
   1 2 3 4 5 6 7 
Binding Energy R0/R1 a −6.9/−6.9 −8.1/−8.1 −5.9/−5.9 −6.5/−6.5 −6.3/−6.3 −6.2/−6.2 −6.6/−6.6 
MM/GBSA   −30.3141 −31.2458 −13.8779 −27.6481 −27.6534 −18.5779 −18.8955 
Binding Energy R0/R1 b −6.8/−6.8 −7.9/−7.9 −5.1/−5.1 −6.6/−6.6 −5.6/−5.6 −5.8/−5.8 −5.9/−5.9 
MM/GBSA   −22.0902 −23.9910 −7.0321 −17.6371 −19.3959 −9.2248 −20.6117 
Binding Energy R0/R1 c −6.8/−6.8 −8.1/−8.1 −5.8/−5.8 −6.3/−6.3 −6.3/−6.3 −6.2/−6.2 −6.7/−6.7 
MM/GBSA   −26.1345 −28.4927 −10.3167 −24.8857 −23.8207 −14.7674 −17.0307 
Binding Energy R0/R1 d −7/−7 −8.1/−8.1 −5.2/−5.2 −6.8/−6.8 −6.5/−6.5 −6.1/−6.1 −6.7/−6.7 
MM/GBSA   −26.2805 −29.6158 −12.1225 −22.7717 −23.6754 −14.4347 −13.6539 
Binding Energy R0/R1 e −7/−7 −8.1/−8.1 −6/−6 −6.7/−6.7 −5.8/−5.8 −6.1/−6.1 −6.7/−6.7 
MM/GBSA   −27.2898  −19.5564 −25.4497 −26.4593 −17.3314 −18.9577 
Binding Energy R0/R1 f −6/−6 −8.2/−8.2 −5.8/−5.8 −6.3/−6.3 −6.2/−6.2 −6/−6 −6.4/−6.4 
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Table A1. Summary of classical rigid docking calculations of the derived analogues compound set over
the GSK3β and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculations of the
best posed analogue compounds. Lowercase letters represent the employed halogen group (a–g).
GSK3β
1 2 3 4 5 6 7
Binding Energy R0/R1 a −6.9/−6.9 −8.1/−8.1 −5.9/−5.9 −6.5/−6.5 −6.3/−6.3 −6.2/−6.2 −6.6/−6.6
MM/GBSA −30.3141 −31.2458 −13.8779 −27.6481 −27.6534 −18.5779 −18.8955
Binding Energy R0/R1 b −6.8/−6.8 −7.9/−7.9 −5.1/−5.1 −6.6/−6.6 −5.6/−5.6 −5.8/−5.8 −5.9/−5.9
MM/GBSA −22.0902 −23.9910 −7.0321 −17.6371 −19.3959 −9.2248 −20.6117
Binding Energy R0/R1 c −6.8/−6.8 −8.1/−8.1 −5.8/−5.8 −6.3/−6.3 −6.3/−6.3 −6.2/−6.2 −6.7/−6.7
MM/GBSA −26.1345 −28.4927 −10.3167 −24.8857 −23.8207 −14.7674 −17.0307
Binding Energy R0/R1 d −7/−7 −8.1/−8.1 −5.2/−5.2 −6.8/−6.8 −6.5/−6.5 −6.1/−6.1 −6.7/−6.7
MM/GBSA −26.2805 −29.6158 −12.1225 −22.7717 −23.6754 −14.4347 −13.6539
Binding Energy R0/R1 e −7/−7 −8.1/−8.1 −6/−6 −6.7/−6.7 −5.8/−5.8 −6.1/−6.1 −6.7/−6.7
MM/GBSA −27.2898 −19.5564 −25.4497 −26.4593 −17.3314 −18.9577
Binding Energy R0/R1 f −6/−6 −8.2/−8.2 −5.8/−5.8 −6.3/−6.3 −6.2/−6.2 −6/−6 −6.4/−6.4
MM/GBSA −26.4517 −6.2475 −23.7315 −19.8909 −13.3104
Binding Energy R0/R1 g −6.2/−6.2 −8.2/−8.2 −5.8/−5.8 −6.5/−6.5 −6.2/−6.2 −6.3/−6.3 −5.9/−5.9
MM/GBSA −28.2864 −14.2501 −24.4026 −24.7124 −16.8986 −20.7272
To avoid false positives, each docking calculation was performed twice (R0/R1). All energies values are kcal/mol.
Table A2. Summary of classical rigid docking calculations of the derived analogues compound set
over the CK1δ and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculations of
the best posed analogue compounds. Lowercase letters represent the employed halogen group (a–g).
CK1δ
1 2 3 4 5 6 7
Binding Energy R0/R1 a −5.1/−5.1 −7.7/−7.7 −5.2/−5.2 −5.3/−5.3 −5.6/−5.6 −5.6/−5.6 −5.3/−5.3
MM/GBSA −35.4499 −3.7149 −26.5327 −26.4630 −18.4901
Binding Energy R0/R1 b −5.8/−5.8 −7.7/−7.7 −5.5/−5.5 −5.3/−5.3 −5.8/−5.8 −5.6/−5.6 −5.2/−5.2
MM/GBSA −24.0479 −30.2266 −21.2435 −6.4142 −11.6429
Binding Energy R0/R1 c −5.6/−5.6 −7.6/−7.6 −4.8/−4.8 −5.7/−5.7 −5.2/−5.2 −5.1/−5.1 −5.6/−5.6
MM/GBSA −29.9803 −19.4546 −22.8644 −26.4159 −12.0871
Binding Energy R0/R1 d −5.9/−5.9 −7.5/−7.5 −4.7/−4.7 −5.5/−5.5 −5.9/−5.9 −5.1/−5.1 −5.5/−5.5
MM/GBSA −19.8892 −25.5694
Binding Energy R0/R1 e −6.1/−6.1 −7.5/−7.5 −5.4/−5.4 −5.3/−5.3 −5.1/−5.1 −5.3/−5.3 −5.3/−5.3
MM/GBSA −37.8982 −28.6573 −28.5831 −16.2323
Binding Energy R0/R1 f −6.2/−6.2 −7.5/−7.5 −5.4/−5.4 −5.2/−5.2 −5.1/−5.1 −5.5/−5.5 −5.4/−5.4
MM/GBSA −34.6944 −22.6616 −26.3915 −13.6562 −15.4050
Binding Energy R0/R1 g −6.1/−6.1 −7.3/−7.3 −4.8/−4.8 −5.2/−5.2 −5.1/−5.1 −5.6/−5.6 −5.5/−5.5
MM/GBSA −33.2393 −28.7631 −26.0731 −28.0238
To avoid false positives, each docking calculation was performed twice (R0/R1). All energies values are kcal/mol.
Table A3. Summary of classical rigid docking calculations of the derived analogues compound set over
the DYRK1A and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculations of
the best posed analogue compounds. Lowercase letters represent the employed halogen group (a–g).
DYRK1A
1 2 3 4 5 6 7
Binding Energy R0/R1 a −6.2/−6.2 −8.6/−8.6 −5.9/−5.9 −6.8/−6.8 −6.7/−6.7 −5.7/−5.7 −6/−6
MM/GBSA −37.8422 −15.2733 −30.7518 −31.2535 −18.9387 −20.8203
Binding Energy R0/R1 b −6.5/−6.5 −8.5/−8.5 −7/−7 −7.2/−7.2 −6.6/−6.6 −7/−7 −7.3/−7.3
MM/GBSA −23.7829 −28.0642 −8.4887 −19.4730 −21.8802 −10.2503 −11.8981
Binding Energy R0/R1 c −6.3/−6.3 −8.6/−8.6 −5.9/−5.9 −7.2/−7.2 −6.5/−6.5 −6.9/−6.9 −7.3/−7.3
MM/GBSA −30.2004 −34.1231 −12.1852 −26.5473 −28.3000 −18.7332 −13.2158
Binding Energy R0/R1 d −5.9/−5.9 −8.6/−8.6 −6.7/−6.7 −6.6/−6.6 −6.3/−6.3 −6.5/−6.5 −6.6/−6.6
MM/GBSA −30.8597 −36.1125 −10.3667 −26.3748 −26.9602 −17.1653 −16.4510
Binding Energy R0/R1 e −6.4/−6.4 −8.6/−8.6 −6.5/−6.5 −6.6/−6.6 −6.4/−6.4 −6.6/−6.6 −6.4/−6.4
MM/GBSA −32.8862 −13.5197 −28.9038 −29.6780 −20.0635
Binding Energy R0/R1 f −6.2/−6.2 −8.6/−8.6 −5.8/−5.8 −6.8/−6.8 −6.3/−6.3 −6.4/−6.4 −6.9/−6.9
MM/GBSA −28.9419 −33.0823 −14.5027 −25.4579 −28.4081 −15.8583 −17.0209
Binding Energy R0/R1 g −6.7/−6.7 −8.7/−8.7 −5.8/−5.8 −6.8/−6.8 −6.7/−6.7 −6.1/−6.1 −6.9/−6.9
MM/GBSA −30.3186 −35.5805 −13.4928 −27.1510 −29.6010 −18.0146 −17.3973
To avoid false positives, each docking calculation was performed twice (R0/R1). All energies values are kcal/mol.
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Table A4. Summary of classical rigid docking calculations of the derived analogues compound set
over the CLK1 and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculations of
the best posed analogue compounds. Lowercase letters represent the employed halogen group (a–g).
CLK1
1 2 3 4 5 6 7
Binding Energy R0/R1 a −7.5/−7.5 −8.8/−8.8 −6.4/−6.4 −6.8/−6.8 −6.2/−6.2 −6.4/−6.4 −6.9/−6.9
MM/GBSA −29.8546 −34.1041 −15.2943 −26.7584 −25.8120 −27.7489 −24.0832
Binding Energy R0/R1 b −7.1/−7.1 −8.4/−8.4 −7/−7 −5.6/−5.6 −7.5/−7.5 −6.6/−6.6 −7.2/−7.2
MM/GBSA −25.9089 −27.3711 −13.7919 −26.2326 −22.1539 −16.6984 −20.9149
Binding Energy R0/R1 c −7.6/−7.6 −9.1/−9.1 −7/−7 −7.3/−7.3 −6.4/−6.4 −6.6/−6.6 −6.4/−6.4
MM/GBSA −34.0221 −16.2165 −24.6708 −29.4190 −25.8368 −20.9436
Binding Energy R0/R1 d −7.6/−7.6 −8.4/−8.4 −6.8/−6.8 −7.8/−7.8 −6.3/−6.3 −6.9/−6.9 −7/−7
MM/GBSA −26.9398 −30.7361 −25.6581 −25.1797 −19.3712 −17.5727
Binding Energy R0/R1 e −6.8/−6.8 −8.9/−8.9 −6.9/−6.9 −7.5/−7.5 −5.9/−5.9 −7.1/−7.1 −7/−7
MM/GBSA −30.0891 −16.2097 −28.3695 −28.0697 −27.0478 −17.4985
Binding Energy R0/R1 f −7.5/−7.5 −8.6/−8.6 −6.7/−6.7 −7.5/−7.5 −6.2/−6.2 −6.4/−6.4 −6.7/−6.7
MM/GBSA −28.1471 −20.4786 −23.9274 −27.3596 −15.4231 −21.2829
Binding Energy R0/R1 g −7/−7 −8.9/−8.9 −6/−6 −7.4/−7.4 −6.8/−6.8 −6.4/−6.4 −6.8/−6.8
MM/GBSA −30.3541 −33.9082 −16.3122 −25.0002 −30.7737 −25.4765
To avoid false positives, each docking calculation was performed twice (R0/R1). All energies values are kcal/mol.
Table A5. Summary of absorption and distribution properties of the entire set of 49 derived compounds
and the four brominated alkaloids convolutamine I (I) and J (J), kororamide A (A) and B (B).
Absorption Distribution




Absorption LogP BBB PPB VDss
CNS
Permeability
Compound 1a 331 −4.8 inactive High 92.328 2.8 0.298 High 0.231 −1.832
Compound 1b 209.2 −3.4 inactive Moderate 94.522 2.6 0.186 Medium 0.131 −1.888
Compound 1c 242.1 −4.3 inactive High 92.462 2.9 0.279 High 0.37 −1.832
Compound 1d 270.1 −4 inactive High 93.463 2.6 0.152 High 0.249 −1.866
Compound 1e 286.6 −4.5 inactive High 92.395 2.8 0.278 High 0.385 −1.832
Compound 1f 270.1 −4 inactive High 93.49 2.6 0.152 High 0.256 −1.87
Compound 1g 286.6 −4.5 inactive High 92.395 2.8 0.278 High 0.385 −1.832
Compound 2a 351 −6.1 inactive Moderate 90.067 4.1 0.477 High 0.234 −0.894
Compound 2b 229.2 −5.1 inactive Moderate 92.006 3.4 0.539 High −0.081 −0.946
Compound 2c 262.1 −5.9 inactive Moderate 90.201 4.6 0.482 High 0.197 −0.894
Compound 2d 306.6 −6.1 inactive Moderate 90.134 4.4 0.48 High 0.215 −0.894
Compound 2e 290.1 −5.7 inactive Moderate 91.036 3.8 0.508 High 0.076 −0.92
Compound 2f 290.1 −5.7 inactive Moderate 91.721 3.8 0.708 High 0.051 −1.339
Compound 2g 306.6 −6.1 inactive Moderate 90.819 4.4 0.68 High 0.196 −1.313
Compound 3a 304 −4.7 inactive High 89.848 2.8 0.227 High 0.95 −1.961
Compound 3b 182.2 −3.4 inactive Moderate 91.82 2.7 0.375 Low 0.764 −2.017
Compound 3c 215.1 −4.2 inactive High 89.982 2.9 0.23 High 0.919 −1.961
Compound 3d 243.1 −4 inactive High 90.899 2.7 0.222 Medium 0.868 −1.999
Compound 3e 259.5 −4.4 inactive High 89.915 2.8 0.228 High 0.934 −1.961
Compound 3f 243.1 −4 inactive High 90.872 2.7 0.222 Medium 0.845 −1.995
Compound 3g 259.5 −4.4 inactive High 89.915 2.8 0.228 High 0.934 −1.961
Compound 4a 289 −4.9 inactive High 91.487 3.3 0.351 High 0.432 −1.66
Compound 4b 167.2 −3.4 inactive Moderate 93.459 3.2 0.437 Medium 0.248 −1.715
Compound 4c 200.1 −4.5 inactive High 91.621 3.6 0.357 High 0.401 −1.66
Compound 4d 228.1 −4.1 inactive High 92.538 3.2 0.382 Medium 0.344 −1.697
Compound 4e 244.5 −4.7 inactive High 91.554 3.5 0.354 High 0.416 −1.66
Compound 4f 228.1 −4.1 inactive High 92.511 3.2 0.382 Medium 0.32 −1.693
Compound 4g 244.5 −4.7 inactive High 91.554 3.5 0.354 High 0.416 −1.66
Compound 5a 305 −4.4 inactive High 89.763 3 0.284 High 0.253 −1.98
Compound 5b 183.2 −2.9 inactive Moderate 91.734 2.6 0.432 Low 0.086 −2.036
Compound 5c 216.1 −3.6 inactive High 89.897 2.7 0.287 High 0.223 −1.98
Compound 5d 244.1 −3.5 inactive High 90.814 2.7 0.279 Medium 0.169 −2.017
Compound 5e 260.5 −3.9 inactive High 89.83 2.9 0.286 High 0.238 −1.98
Compound 5f 244.1 −3.5 inactive High 90.786 2.7 0.279 Medium 0.143 −2.014
Compound 5g 260.5 −3.9 inactive High 89.83 2.9 0.286 High 0.238 −1.98
Compound 6a 318 −4.7 inactive High 90.757 2.7 0.146 High 1.061 −1.917
Compound 6b 196.2 −3.2 inactive Moderate 92.728 2.7 0.293 Low 0.867 −1.973
Compound 6c 229.1 −4.3 inactive High 90.891 3 0.148 Medium 1.031 −1.917
Compound 6d 257.1 −3.9 inactive High 91.78 2.6 0.14 Medium 0.956 −1.951
Compound 6e 273.6 −4.4 inactive High 90.824 2.8 0.147 Medium 1.046 −1.917
Compound 6f 257.1 −3.9 inactive High 91.808 2.6 0.14 Medium 0.978 −1.954
Compound 6g 273.6 −4.4 inactive High 90.824 2.8 0.147 Medium 1.046 −1.917
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Table A5. Cont.
Absorption Distribution




Absorption LogP BBB PPB VDss
CNS
Permeability
Compound 7a 332 −4.9 inactive High 92.246 3 0.191 High 1.141 −1.487
Compound 7b 210.2 −3.4 inactive Moderate 94.218 2.9 0.349 Low 0.994 −1.543
Compound 7c 243.1 −4.6 inactive High 92.38 3.3 0.225 Medium 1.11 −1.487
Compound 7d 271.1 −4.1 inactive High 93.297 2.9 0.258 Medium 1.084 −1.525
Compound 7e 287.6 −4.7 inactive High 92.313 3.2 0.208 High 1.125 −1.487
Compound 7f 271.1 −4.1 inactive High 93.27 2.9 0.258 Medium 1.055 −1.521
Compound 7g 287.6 −4.7 inactive High 92.313 3.2 0.208 High 1.125 −1.487
J 470 −4.4 inactive Moderate 90.483 4.4 0.386 High 0.868 −2.215
I 473 −4.3 inactive Moderate 91.515 3.9 0.193 High 1.474 −2.024
A 534.1 −4.3 inactive Low 90.979 4.6 0.316 Low 1.112 −2.449
B 535.1 −3.9 inactive Moderate 100 3.4 0.184 High 0.002 −2.93
BBB: blood brain barrier, PPB: protein-protein binding, VDss: steady state volume of distribution, CNS: central
nervous system.
Table A6. Summary of metabolism, excretion and toxicity properties of the entire set of 49 derived
compounds and the four brominated alkaloids convolutamine I (I) and J (J), kororamide A (A) and B (B).
Metabolism Excretion Toxicity
Compound CYP450 OCT2 Substrate hERG MRTD AMESToxicity Hepatotoxicity
Compound 1a Yes No <4.0 0.482 No No
Compound 1b Yes No <4.0 0.666 No No
Compound 1c Yes No <4.0 0.503 No No
Compound 1d Yes No <4.0 0.45 No No
Compound 1e Yes No <4.0 0.492 No No
Compound 1f Yes No <4.0 0.574 No No
Compound 1g Yes No <4.0 0.492 No No
Compound 2a Yes No <4.0 0.673 Yes No
Compound 2b Yes No <4.0 0.608 Yes No
Compound 2c Yes No <4.0 0.671 Yes No
Compound 2d Yes No <4.0 0.672 Yes No
Compound 2e Yes No <4.0 0.641 Yes No
Compound 2f Yes No <4.0 0.585 Yes No
Compound 2g Yes No <4.0 0.616 Yes No
Compound 3a Yes No <4.0 0.381 No No
Compound 3b Yes No <4.0 0.512 No No
Compound 3c Yes No <4.0 0.402 No No
Compound 3d Yes No <4.0 0.455 No No
Compound 3e Yes No <4.0 0.391 No No
Compound 3f Yes No <4.0 0.303 No No
Compound 3g Yes No <4.0 0.391 No No
Compound 4a Yes No <4.0 0.525 No No
Compound 4b Yes No <4.0 0.716 No No
Compound 4c Yes No <4.0 0.544 No No
Compound 4d Yes No <4.0 0.625 No No
Compound 4e Yes No <4.0 0.534 No No
Compound 4f Yes No <4.0 0.471 No No
Compound 4g Yes No <4.0 0.534 No No
Compound 5a Yes No <4.0 0.55 No No
Compound 5b Yes No <4.0 0.678 No No
Compound 5c Yes No <4.0 0.572 No No
Compound 5d Yes No <4.0 0.627 No No
Compound 5e Yes No <4.0 0.561 No No
Compound 5f Yes No <4.0 0.47 No No
Compound 5g Yes No <4.0 0.561 No No
Compound 6a Yes No <4.0 0.376 No No
Compound 6b Yes No <4.0 0.502 No No
Compound 6c Yes No <4.0 0.397 No No
Compound 6d Yes No <4.0 0.293 No No
Compound 6e Yes No <4.0 0.387 No No
Compound 6f Yes No <4.0 0.441 No No
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Table A6. Cont.
Metabolism Excretion Toxicity
Compound CYP450 OCT2 Substrate hERG MRTD AMESToxicity Hepatotoxicity
Compound 6g Yes No <4.0 0.387 No No
Compound 7a Yes No <4.0 0.2 No No
Compound 7b Yes No <4.0 0.311 No No
Compound 7c Yes No <4.0 0.219 No No
Compound 7d Yes No <4.0 0.259 No No
Compound 7e Yes No <4.0 0.209 No No
Compound 7f Yes No <4.0 0.117 No No
Compound 7g Yes No <4.0 0.209 No No
I Yes Yes <4.0 0.029 No Yes
J Yes Yes <4.0 −0.814 No Yes
A Yes No <4.0 −0.599 No Yes
B No No <4.0 0.405 Yes No
CYP: cytochrome, OCT2: organic cation transporter 2, hERG: human ether-a-go-go gene, MRTD: maximum
recommended tolerated dose.
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